Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study

Active, not recruiting

• Conditions: Prostate Cancers

• Registration Number: NCT06929884
• Lead Sponsor: Qianfoshan Hospital

Brief Summary

Prostate cancer (PC) is the most common malignancy in the male genitourinary system. In China, both the incidence and mortality rates of PC have shown a significant upward trend in recent years. Chinese patients are typically diagnosed at older ages with higher preoperative prostate-specific antigen (PSA) levels compared to Western populations, indicating a more aggressive disease phenotype. This may explain the lower 5-year survival rates in Chinese PC patients. Over the past three decades, the age-standardized incidence of PC in China has surged by 95.2%, while the global rate increased by only 13.2%. Conversely, global PC mortality decreased by 15.7%, whereas China saw a mere 5.3% reduction. The high economic burden on patients and healthcare systems underscores the urgency of optimizing treatment strategies. Direct annual medical costs for PC in China average $3,500 per patient, with drug expenses accounting for over 60% and out-of-pocket payments comprising approximately 20%. These costs far exceed those of other malignancies, posing sustainability challenges for families and insurance systems. Androgen deprivation therapy (ADT), including surgical or chemical castration, remains the cornerstone for advanced PC. Chemical castration via luteinizing hormone-releasing hormone (LHRH) agonists or antagonists offers comparable survival benefits to surgical castration but with improved quality of life. Goserelin, a synthetic GnRH analog, has been widely used since 1987. Current formulations include a sustained-release implant (10.8 mg/3.6 mg) administered subcutaneously every 28 days using a 16G needle (outer diameter: 1.6 mm), which may cause injection-site injuries, and a newer microsphere formulation (3.6 mg) delivered intramuscularly via a 21G needle (outer diameter: 0.8 mm), enhancing patient tolerance. While Phase III trials showed no significant efficacy differences between the two formulations, real-world evidence is lacking. This retrospective cohort study aims to evaluate the effectiveness, safety, and cost-effectiveness of both formulations using real-world data.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-02
• Status Verified: 2025-04
• Study First Submitted: 2025-04-08
• Study First Submitted QC: 2025-04-08
• Last Update Submitted: 2025-04-08
• Study First Posted: 2025-04-16
• Last Update Posted: 2025-04-16
• Primary Completion: 2025-05-01
• Study Completion: 2025-05-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Male
• Target Recruitment: 400

Inclusion Criteria

• 1. Patients with histologically confirmed prostate cancer (PC) deemed suitable for endocrine therapy (excluding neoadjuvant endocrine therapy).

2. At least 18 years old 3. Prescribed 3.6 mg goserelin every 4 weeks as monotherapy or in combination with anti-androgen therapy.

Exclusion Criteria

• 1. Hypersensitivity to LHRH, its analogs, or any component of goserelin. 2. Previous or concurrent hormone therapy, except for conventional anti-androgen therapy administered within 2 weeks before goserelin treatment.

  2. Diagnosis or suspicion of hormone-resistant PC, history of hypophysectomy, adrenalectomy, or pituitary lesions.

  4.Scheduled for radical radiotherapy (adjuvant radiotherapy post-radical prostatectomy [RP] combined with goserelin is permitted) or planned neoadjuvant hormone therapy prior to RP.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum testosterone	baseline, 1, 6, 12, and >12 months	Serum testosterone
PSA levels	baseline, 1, 6, 12, and >12 months
percentage of patients achieving testosterone suppression (≤50 ng/dL and ≤20 ng/dL)	baseline, 1, 6, 12, and >12 months
digital rectal examination (DRE)	baseline, 1, 6, 12, and >12 months

Secondary Outcome Measures

Name	Time	Method
Imaging results (bone scans, pelvic/abdominal imaging), treatment adherence, adverse events (injection-site reactions), metabolic changes, hepatic/renal dysfunction), and cost-effectiveness analysis (CEA).	>12 months

Trial Locations

Locations (1)

Shandong Provincial Qianfoshan Hospital; 🇨🇳 Jinan, Shandong, China